Predictors of Infliximab Failure After Azathioprine Withdrawal in Crohn's Disease Treated With Combination Therapy
The DOI matches its Crossref record.
Abstract
OBJECTIVES: Whether all Crohn's disease (CD) patients should maintain long-term azathioprine treatment in combination with infliximab remains controversial. We analyzed the predictive factors of infliximab failure after azathioprine withdrawal. METHODS: This was an observational study from a single referral center. All patients with luminal CD in remission who stopped azathioprine after receiving infliximab in combination with azathioprine for at least 6 months were studied. Cumulative probabilities of infliximab failure-free survival were estimated by the Kaplan-Meier method from the date of azathioprine withdrawal to the date of infliximab failure or last known follow-up. Infliximab failure was defined by: (i) disease flare requiring shortening of the dosing interval or increasing the infliximab dose to 10 mg/kg, or switching to adalimumab; (ii) acute or delayed hypersensitivity reactions leading to infliximab discontinuation; or (iii) CD-related surgery. RESULTS: At last known follow-up, 35 out of 48 (73%) patients were infliximab failure free. The survival probabilities were 85% (+/-5%) at 12 months and 41% (+/-18%) at both 24 and 32 months. Cox proportional-hazards regression identified three predictors of infliximab failure: infliximab-azathioprine exposure duration of < or = 811 days (hazard ratio (HR)=7.46, P=0.01), C-reactive protein > 5 mg/l (HR=4.79, P=0.008), and platelet count > 298 10(9)/l (HR=4.75, P=0.02). CONCLUSIONS: In CD in clinical remission under azathioprine-infliximab combination therapy, azathioprine withdrawal is associated with a high risk of relapse in patients with a duration of combination therapy of < 27 months and/or the presence of biological inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Epidemiology and Natural History of Inflammatory Bowel Diseases
Cosnes, J., Gower–Rousseau, C., Seksik, P., & Cortot, A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.055 · Cited by 2,211
Guidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease
Ruemmele, F. M., Veres, G., Kolho, K. L., Griffiths, A., Levine, A., Escher, J. C., Amil Dias, J., Barabino, A., Braegger, C. P., Bronsky, J., et al. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.04.005 · Cited by 1,083
The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease
Lewis, J. D. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.058 · Cited by 458
Torres, J., Boyapati, R. K., Kennedy, N. A., Louis, E., Colombel, J.-F., & Satsangi, J. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.055 · Cited by 225
Biomarkers in inflammatory bowel disease: current practices and recent advances.
Iskandar, H. N., & Ciorba, M. A. (2012) · Translational Research · doi:10.1016/j.trsl.2012.01.001 · Cited by 210
“In patients on concomitant immunosuppressive therapy for CD, elevated CRP (>5) or elevated platelet count (>298) at time of azathioprine withdrawal was predictive of future infliximab failure.(35) Though not highly sensitive, several studies have shown CRP elevations to be predictive of recurrence with CD.”
BackgroundTailoring anti-TNF therapy in IBD: drug levels and disease activity
Ben-Horin, S., & Chowers, Y. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.253 · Cited by 192
Positioning and usefulness of biomarkers in inflammatory bowel disease
Sakurai, T., & Saruta, M. (2023) · Digestion · doi:10.1159/000527846 · Cited by 156
Metadata
- Authors
- Oussalah, A., Chevaux, J.-B., Fay, R., Sandborn, W. J., Bigard, M.-A., & Peyrin-Biroulet, L.
- Venue
- American Journal of Gastroenterology
- Published
- 2010-05
- Volume
- 105
- Issue
- 5
- Pages
- 1142-1149
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W1993355087
- Cited by
- 96
- References
- 0
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.